BRIEF published on 04/07/2026 at 07:05, 2 months ago Aelis Farma obtient une subvention de 458 000 € pour son programme de lutte contre l'obésité France 2030 Aelis Farma Récepteur CB1 Recherche Sur L'obésité Subvention De Nouvelle-Aquitaine
BRIEF published on 04/07/2026 at 07:05, 2 months ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 2 months ago Informations privilégiées / Autres communiqués Aelis Farma reçoit 458 k€ de subvention de France 2030 en Nouvelle-Aquitaine pour son programme innovant dans l'obésité et les maladies métaboliques. Soutien non dilutif pour la recherche sur les traitements des désordres métaboliques Subvention France 2030 Obésité Aelis Farma Nouvelle-Aquitaine
PRESS RELEASE published on 04/07/2026 at 07:00, 2 months ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 2 months 17 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
BRIEF published on 03/21/2026 at 10:10, 2 months 17 days ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
PRESS RELEASE published on 03/21/2026 at 10:05, 2 months 17 days ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
PRESS RELEASE published on 03/21/2026 at 10:05, 2 months 17 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 4 months 26 days ago Aelis Farma obtient un avis favorable de l'EMA pour AEF0217 dans la trisomie 21 EMA Aelis Farma Trisomie 21 AEF0217 Développement Pédiatrique
BRIEF published on 01/12/2026 at 07:35, 4 months 26 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
Published on 06/06/2026 at 04:45, 1 day 5 hours ago Battery X Metals Announces Closing of First Tranche of Private Placement to Advance Corporate Growth
Published on 06/06/2026 at 00:00, 1 day 10 hours ago Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
Published on 06/05/2026 at 17:00, 1 day 17 hours ago Silver Spruce Resources Inc. Provides an Update on the Jackie Project Acquisition
Published on 06/05/2026 at 15:00, 1 day 19 hours ago Norsemont Drills 20 Meters of 1.20 G/T Gold Equivalent at Bottom of Hole
Published on 06/05/2026 at 13:30, 1 day 21 hours ago CANEX Announces Gold Basin Resources Shareholders Approve Merger Arrangement With CANEX With 75.82% Support
Published on 06/06/2026 at 08:29, 1 day 2 hours ago Starting today, Trade Republic gives European retail investors direct access to IPOs
Published on 06/06/2026 at 00:20, 1 day 10 hours ago Guild Wars 3, Modern Evolution of the MMORPG, Announced at Summer Game Fest for PC and PlayStation 5
Published on 06/05/2026 at 23:05, 1 day 11 hours ago Quantinuum Announces Closing of Upsized Initial Public Offering
Published on 06/05/2026 at 19:06, 1 day 15 hours ago EQS-Adhoc: Brockhaus Technologies AG: The Company's Management Board intends to return approx. €180 million of the proceeds from the sale of the Bikeleasing Group to shareholders
Published on 06/05/2026 at 18:48, 1 day 15 hours ago Digital transformation journey takes centre stage at ANGOTIC 2026
Published on 06/05/2026 at 19:00, 1 day 15 hours ago ALTAREA - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 06/05/2026 at 19:00, 1 day 15 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 06/05/2026 at 19:00, 1 day 15 hours ago ALTAREIT - Descriptif du programme de rachat d'actions autorisé par l'assemblée générale mixte du 4 juin 2026 et mis en œuvre par la Gérance
Published on 06/05/2026 at 19:00, 1 day 15 hours ago ALTAREA : Descriptif du programme de rachat d'actions autorisé par l'assemblée générale mixte du 4 juin 2026 et mis en œuvre par la Gérance
Published on 06/05/2026 at 19:00, 1 day 15 hours ago ALTAREIT - DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES MAI 2026
